PMID: 7023650Sep 1, 1981Paper

High-dose combination chemotherapy for acute nonlymphoblastic leukemia in adults

Cancer
H GlucksbergE D Thomas

Abstract

One hundred thirty-nine consecutive unselected adults with acute nonlymphoblastic leukemia were treated with a high-dose chemotherapeutic remission-induction regimen consisting of daunomycin (70 mg/m2 IV on days 1, 2, 3), cytosine arabinoside (100 mg/m2 IV every 12 hours), 6-thioguanine (100 mg/m2 orally every 12 hours), prednisone (40 mg/m2 daily), all given on days 1 through 7, and vincristine (1 mg/m2 IV on days 1 and 7). Supportive care consisted of broad spectrum antibiotics for fever in the presence of granulocytopenia and prophylactic platelet transfusions. The complete remission (CR) rate was 60%. The median number of days to CR was 30. Fifty-eight of 77 (75%) patients under age 50 and 26 of 62 (42%) patients over age 50 attained CR. Despite the use of a relatively large dose of daunomycin and monthly maintenance chemotherapy, the median remission duration was only 39 weeks and the medial survival 64 weeks. Most patients who failed to achieve CR died early-77% of deaths occurred within the first six weeks. Infections accounted for the increase mortality in patients over age 50. Thirty-seven percent of patients over age 50 died of infections whereas only 10% under age 50 did so (P less than 0.001). Seven percent of the p...Continue Reading

References

Dec 1, 1978·Annals of Internal Medicine·C D BucknerE D Thomas
Mar 5, 1977·Lancet·R P Gale, M J Cline
Jul 23, 1977·Lancet·B A Peterson, C D Bloomfield
Aug 1, 1979·Cancer·G P BodeyE J Freireich
Dec 1, 1977·British Journal of Cancer·J K ReesF G Hayhoe
Mar 31, 1977·The New England Journal of Medicine·J B AlaviR A Cooper
Sep 13, 1979·The New England Journal of Medicine·E D ThomasP L Weiden
May 11, 1978·The New England Journal of Medicine·R A CliftC D Buckner
Dec 1, 1976·Archives of Internal Medicine·E J FreireichJ P Hester
Aug 1, 1975·Cancer·B D ClarksonJ H Burchenal
Sep 1, 1975·Archives of Internal Medicine·P T Goodall, K L Vosti
May 1, 1976·Medicine·H Y ChangE J Freireich
Jun 1, 1972·The New England Journal of Medicine·D S Rosenthal, W C Moloney
Aug 1, 1972·Cancer·H S Mirsky, J Cuttner
Aug 24, 1972·The New England Journal of Medicine·R G GrawE S Henderson
Jun 1, 1966·Journal of Chronic Diseases·G P Bodey
Jan 1, 1963·Cancer·J G GRUHN, J SANSON

❮ Previous
Next ❯

Citations

Jan 1, 1992·International Journal of Clinical & Laboratory Research·Z A ArlinH G Chun
Oct 1, 1991·Pharmacology & Therapeutics·E K Rowinsky, R C Donehower
Mar 24, 1984·Lancet·R E MarcusD A Galton
Oct 14, 1998·Japanese Journal of Clinical Oncology·I SekineN Saijo
Feb 1, 1992·Antimicrobial Agents and Chemotherapy·K NomotoK Nomoto
Apr 24, 1982·British Medical Journal·R BellT A Lister
Jan 1, 1983·Critical Reviews in Clinical Laboratory Sciences·P L Weiden
Jan 11, 1992·Leukemia·M E Nesbit, W G Woods
Jan 1, 1991·Baillière's Clinical Haematology·J P Marie, R Zittoun
Mar 1, 1992·Blood Reviews·K A Foon, R P Gale
Mar 1, 1984·British Journal of Haematology·A M Worsley, D A Galton
Sep 1, 1988·Journal of Clinical Pharmacology·E L Schwartz, P H Wiernik
Apr 1, 1987·Cancer·H M KantarjianE J Freireich
Nov 14, 1997·Clinical Pharmacology and Therapeutics·R E Vestal, P Calabresi
Jun 5, 2020·Journal of Comparative Effectiveness Research·Zahra BagheriHossein Khalili
Jan 1, 1991·Leukemia & Lymphoma·L AngelovA Keating
Mar 1, 1985·Scandinavian Journal of Haematology·M K Jensen, G Ahlbom
Jan 1, 1984·Scandinavian Journal of Haematology·B NorbergA Wahlin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.